Civica
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: China’s healthcare reforms, a blessing or a threat?

Michael Custer, analyst at Solidiance in Shanghai, explains that healthcare service providers will come out on top from China’s healthcare reforms.

Until now, China’s healthcare system has served the rapidly developing country well. China impressively succeeded in its efforts to achieve universal healthcare coverage, bringing the insured rate up from 50% in 2005 to 95% by 2011. And, despite achieving universal coverage – a rarity for developing countries – the country has been able to keep costs relatively in check, spending just 5.5% of GDP on healthcare in 2014.

Two trends, however, are threatening the long-term sustainability of China’s system. First, China is experiencing a rapidly aging population. China’s old age dependency ratio, a reliable predictor of healthcare costs, will match that of modern day Japan by 2045.

Second, more of its population is becoming unhealthy. The rates of many chronic diseases as well as cancer are on the rise in China due to pollution, poor diet and unhealthy lifestyle choices. To put this in perspective, the diabetes rate in China is already higher than that of the US.

Without enforcing any reforms to the current system, these trends will lead to enormous strains on the government’s budget. According to Solidiance’s white paper titled “China Healthcare Reforms: Who Will Survive?”, it is projected that 20% of China’s government budget will be allocated to healthcare by 2045. That figure is nearly double what it is today, and behind only New Zealand and the United States.

Under more realistic scenarios, considering China’s growing health problems and an increased share in healthcare funded by the government, the share of state budget allocated towards healthcare will range from 24% to 33% – figures that are by far the largest in the world.

Without change, China’s current healthcare system will become unaffordable. The latest round of reforms, launched towards the end of 2015, are thus aimed at ensuring sustainability by reducing costs so as to create a more efficient healthcare system to its people.

For foreign medical device manufacturers and pharmaceutical companies, the reforms are especially worrisome, as the government is increasing the downward price pressure on both industries. The pharmaceutical industry, which makes up a much larger portion of healthcare spending in China than the device industry, is expected to feel the initial brunt of regulatory pressure.

Despite the reforms adding additional complexity, it is important to remember that China’s healthcare market is large and growing rapidly, with value projected to surpass US$1 trillion by 2020. With a market of that size, there are endless strategies that both foreign pharmaceutical and medical device companies can pursue to ensure a piece of the pie and capitalise on opportunities in China.

A key strategy suggested for multinational companies is to focus on developing and introducing new products. Innovative drugs and medical devices will continue to demand a premium in post-reform China. Additionally, maintaining the edge that foreign multinationals have in r&d and technology is crucial for future success as another emphasis of the reforms is to increase the technical capabilities of domestic healthcare companies, especially in the medical device sector.

Healthcare service providers, on the other hand, will benefit the most out of these reforms. China’s healthcare system is currently highly centralised. Chinese citizens tend to settle for level 3 public hospitals, widely regarded as the country’s best hospitals, to treat everything ranging from the common cold to cancer.  This results in over-utilisation of level 3 hospitals and under-utilisation of clinics, level 1, and level 2 hospitals. This centralisation and lack of efficiency within the public healthcare system is unsustainable and results in poor quality, especially in specialty medicine, and significantly higher costs for the government.

The ultimate goal of enforcing these reforms is to move the Chinese system towards a more decentralised model such as those employed in Europe. To do this, the government is aiming to administer a hierarchal system of healthcare, encourage the development and utilisation of private facilities, and develop a nationwide system of general practitioners. It is this supportive regulatory environment combined with a growing middle class that is beginning to demand better quality healthcare services that will continue to fuel the growth in the private healthcare industry, resulting in increased foreign investment in the healthcare service sector within China.

The Solidance white paper “China Healthcare Reforms: Who Will Survive?” can be downloaded here.

Posted on: 09/03/2017 UTC+08:00


News

China Cord Blood Corporation (CCBC), the country’s largest provider of cord blood storage and ancillary services, has reported a 38.7% rise in profits for the full year to 31 March of Rmb126.2 million (US$18.3 million). At the same time, revenues were up 14.6% to Rmb760 million.
Beijing-based Baheal Pharmaceutical Group plans to bring IBM Watson Health’s Watson for Genomics to clinicians across China. The new multi-year agreement comes less than three months after Baheal and IBM launched a strategic alliance to distribute Watson for Oncology in China. The plan is to establish an ecosystem within China to sell the molecular data interpretation technology to clinicians and researchers across the country. Financial terms have not been disclosed.
Medical insurance provider ALC Health has been confirmed as a Lloyd's Coverholder in Hong Kong. ALC Health, a subsidiary of global benefits and assistance services provider International Medical Group, has also opened an office in Hong Kong, appointing Harry Amende as business development executive.
Malaysian examination glove manufacturer Comfort Glove has reported a profit of M$10.1 million (US$2.4 million) for the first quarter of the year. This is a significant increase on the same period last year when the company was hit by a fire. Quarter-on-quarter, revenues were up 29% to M$93.7 million.
Thanks to listing costs, Hong Kong care home operator Pine Care Group has reported a 54.5% slump in profits for the year to 31 March to HK$12.4 million (US$1.6 million). At the same time, revenues were up 2.6% to HK$177.3 million.
Shares in Sydney-based medical appointment booking service 1st Group jumped 22.2% yesterday after the group announced an agreement with Australian leading health advertising and content provider, Tonic Health Media.
Shares in Australian medtech company Resonance Health rose 3.7% yesterday after Thalassaemia International Federation (TIF), a leading patient organisation in the field of iron overload, endorsed its technology which measures liver iron concentration.
US life science technology company Sanovas has agreed to set up a US$75 million venture capital fund and innovation centre with the People's Government of Suzhou. The centre will be based at the Suzhou Institute of Nanotechnology and NanoBionics (SINANO) at the Chinese Academy of Sciences located within the Suzhou Industrial Park Biotechnology Innovation Centre.



Analysis

Brisbane-based Oventus has had a good week. First and foremost the sleep disorder device manufacturer has just completed the first tranche of capital raising. It has raised A$6.5 million (US$4.9 million) in a placement of shares at A$0.36 per share. A second tranche to raise A$0.5 million will follow subject to shareholder approval. Bell Potter is managing the deal.
A new report from QBE Insurance, Australia's largest global insurer, reveals that 22% of healthcare companies in Hong Kong have suffered from legal and regulatory compliance issues over the past 12 months. The Risks of Regret report looks at both current and future business challenges and opportunities, and how well-prepared companies are to deal with risks.
“The Asia-Pacific region presents lucrative opportunities for multinational pharmaceutical firms that treat diabetes,” says BMI Research in Singapore in a new report on healthcare in Asia. Fuelled by rapid urbanisation, nutrition transition and increasingly sedentary lifestyles, the epidemic has grown in parallel with the worldwide rise in obesity. Asia’s large population and rapid economic development have made it an epicentre of the epidemic, with India and China the key hotspots in the region, it explains.
Susann Roth, senior social development specialist, Asian Development Bank, explains why the ADB is committed to doubling health sector investments by 2020.
SGX-listed private healthcare provider Health Management International (HMI) has reported an actual loss in profits for the third quarter of the year of M$1.6 million (US$370,000), though stripping out exceptional items, profits were up 12% to M$7.1 million. The loss was predominantly down to one-off fees of M$7.3 million incurred during the group’s M$556.5 million consolidation of its two hospitals in Malaysia, however profits were also eroded by M$1.3 million in forex losses thanks to a weakening ringgit.
Shares in Cayman Islands-incorporated G Medical Innovations, which develops mobile health technologies, declined heavily on their ASX debut yesterday, dropping 30%.
Singapore-listed property developer Perennial Real Estate has reported a 356% rise in profits for the first quarter of the year to S$38.7 million (US$27.5 million) thanks to divestment gains in Singapore. Revenues for the same period slumped 31.5% to S$20.2 million largely due to lower project management fees and lower rental revenue.
First quarter results from Indonesian healthcare companies have been subdued. There is a sense of marking time rather than any major move forward for any of them. Indeed with the exception of Siloam International Hospitals, the country’s largest private hospital operator, the share price of its healthcare rivals are all showing a loss for the year.



The Future of Healthcare in Asia

Round table

Download the round table here




Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices